Medical Consequences of Drug Abuse and Co-occurring Infections: Research at the National Institute on Drug Abuse

Overview

Journal Subst Abus

Publisher Sage Publications

Specialties Medical Education
Psychiatry

Date 2008 Dec 2

PMID 19042203

Citations 18

Authors

Jag H Khalsa

Glenn Treisman

Elinore McCance-Katz

Ellen Tedaldi

Affiliations

Soon will be listed here.

Abstract

Substance abuse still remains one of the major problems in the world today, with millions of people abusing legal and illegal drugs. In addition, a billion people may also be infected with one or more infections. Both drugs of abuse and infections are associated with enormous burden of social, economic, and health consequences. This article briefly discusses a few medical consequences of drugs of abuse and infections such as human immunodeficiency virus, hepatitis C virus, psychiatric complications in hepatitis C infection, pharmacokinetic drug-drug interactions among medications used in the treatment of addiction and infections, and new drugs in development for the treatment of infections. Research is encouraged to study interactions between infections, drugs of abuse, and underlying pathophysiologic and molecular/genetic mechanisms of these interactions.

Citing Articles

Cognitive Intraindividual variability in injection drug use among Hispanic residents of Puerto Rico.

Chiou K, Feiger J, Snyder R, Davila C, Gocci Carrasco N, Bennett S Appl Neuropsychol Adult. 2024; :1-8.

PMID: 39180514 PMC: 11847948. DOI: 10.1080/23279095.2024.2389564.

Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway.

Rolova G, Skurtveit S, Gabrhelik R, Mravcik V, Odsbu I Addict Sci Clin Pract. 2024; 19(1):37.

PMID: 38741162 PMC: 11092244. DOI: 10.1186/s13722-024-00467-5.

Providing holistic end-of-life care for people with a history of problem substance use: a mixed methods cohort study of interdisciplinary service provision and integrated care.

Webb L, Yarwood G, Witham G, Wright S, Galvani S BMC Palliat Care. 2024; 23(1):86.

PMID: 38556868 PMC: 10983728. DOI: 10.1186/s12904-024-01416-4.

Spectrum of substance use precipitating rehabilitative services among adult patients in the university of Port Harcourt teaching hospital.

Okeafor C, Esu I Afr Health Sci. 2024; 23(3):714-723.

PMID: 38357179 PMC: 10862572. DOI: 10.4314/ahs.v23i3.82.

Bio-Psycho-Social Profile of People with Substance Use Disorders Treated in Locally Assigned Treatment Facilities in Kandahar, Afghanistan.

Stanikzai M, Wahidi M Subst Abuse Rehabil. 2023; 14:89-98.

PMID: 37576434 PMC: 10417592. DOI: 10.2147/SAR.S412821.

References

Gayle H . An overview of the global HIV/AIDS epidemic, with a focus on the United States. AIDS. 2000; 14 Suppl 2:S8-17. View

Lohmann V, KORNER F, Koch J, Herian U, Theilmann L, Bartenschlager R . Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999; 285(5424):110-3. DOI: 10.1126/science.285.5424.110. View

Chung R, Andersen J, Volberding P, Robbins G, Liu T, Sherman K . Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004; 351(5):451-9. PMC: 4113392. DOI: 10.1056/NEJMoa032653. View

Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A . Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004; 292(23):2839-48. DOI: 10.1001/jama.292.23.2839. View

von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T . Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129(2):522-7. DOI: 10.1016/j.gastro.2005.05.008. View

Lucas G, Cheever L, Chaisson R, Moore R . Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001; 27(3):251-9. DOI: 10.1097/00126334-200107010-00006. View

Himelhoch S, Moore R, Treisman G, Gebo K . Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy?. J Acquir Immune Defic Syndr. 2004; 37(4):1457-63. DOI: 10.1097/01.qai.0000136739.01219.6d. View

Braitstein P, Li K, Kerr T, Montaner J, Hogg R, Wood E . Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone. AIDS Care. 2006; 18(7):690-3. DOI: 10.1080/09540120500359330. View

Salloum I, Thase M . Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord. 2001; 2(3 Pt 2):269-80. DOI: 10.1034/j.1399-5618.2000.20308.x. View

10.

Lai S, Lima J, Lai H, Vlahov D, Celentano D, Tong W . Human immunodeficiency virus 1 infection, cocaine, and coronary calcification. Arch Intern Med. 2005; 165(6):690-5. DOI: 10.1001/archinte.165.6.690. View

11.

Himelhoch S, Medoff D . Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS. 2005; 19(12):813-22. DOI: 10.1089/apc.2005.19.813. View

12.

Balasubramanian A, Koziel M, Groopman J, Ganju R . Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV. Clin Infect Dis. 2005; 41 Suppl 1:S32-7. DOI: 10.1086/429493. View

13.

Huckans M, Loftis J, Blackwell A, Linke A, Hauser P . Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders. Subst Abuse Treat Prev Policy. 2007; 2:4. PMC: 1781072. DOI: 10.1186/1747-597X-2-4. View

14.

Nair M, Schwartz S, Mahajan S, Tsiao C, Chawda R, Whitney R . Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO. J Neuroimmunol. 2004; 157(1-2):56-60. DOI: 10.1016/j.jneuroim.2004.08.040. View

15.

Hogan P, Dall T, Nikolov P . Economic costs of diabetes in the US in 2002. Diabetes Care. 2003; 26(3):917-32. DOI: 10.2337/diacare.26.3.917. View

16.

Quaglio G, Lugoboni F, Pajusco B, Sarti M, Talamini G, Lechi A . Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis. 2003; 37(1):33-40. DOI: 10.1086/375566. View

17.

Chung R . Assessment of efficacy of treatment in HCV: infection and disease. J Hepatol. 2005; 44(1 Suppl):S56-9. DOI: 10.1016/j.jhep.2005.11.013. View

18.

El-Serag H, Kunik M, Richardson P, Rabeneck L . Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002; 123(2):476-82. DOI: 10.1053/gast.2002.34750. View

19.

Law M . Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group. J Gastroenterol Hepatol. 1999; 14(11):1100-7. DOI: 10.1046/j.1440-1746.1999.02014.x. View

20.

MacDonald M, Wodak A, Dolan K, van Beek I, Cunningham P, Kaldor J . Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Med J Aust. 2000; 172(2):57-61. DOI: 10.5694/j.1326-5377.2000.tb139199.x. View